February 11, 2016; Washington, DC — BioInformant announces the February 2016 release of its global strategic report, “Stem Cell Research Products, Opportunities, Tools, and Technologies” with market size, segments, trends, and projections to 2020.
The first and only market research firm to specialize in the stem cell industry, BioInformant has more than a decade of historical information on all segments of the stem cell market, by stem cell type. This powerful 175 page global strategic report contains market size, segments, trends, and projections through 2020, as well a social analytics and an end-user survey of nearly 300 stem cell scientists. The “Survey of Stem Cell Scientists” identifies technical requirements, unmet needs, and purchasing preferences of stem cell researchers worldwide.
Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into mature cell types. Commonly investigated stem cell types include embryonic stem cells (ESCs), as well as adult stem cell types, such as mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), neural stem cells (NSCs), and induced pluripotent stem cells (iPSCs). A variety of other stem cell types exist as well.
Stem cells have generated substantial commercial interest, because their potential applications range from cell therapy applications, to tissue regeneration, drug development and discovery, pharmacological testing on cell-specific tissues, toxicology screening, and more. To facilitate research resulting from interest in these far-ranging applications, a large and growing stem cell research products market has emerged.
Major players within the stem cell research products marketplace include Thermo Fisher Scientific, Miltenyi Biotec, Merck KGaA, Lonza Group, STEMCELL Technologies, BD Biosciences (a division of Becton Dickinson), Clontech (a Takara Bio Company), and GE Healthcare Life Sciences. Many small, mid-sized, and specialty providers also compete within the marketplace.
According to BioInformant’s President/CEO, Cade Hildreth, “We have helped hundreds of the top companies increase revenue from stem cell products and decrease risk. Stem cell market intelligence can position companies to approach institutional investors for fundraising, guide internal decision-making, and reduce the risk traditionally associated with new product development.”
BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Center for BioNetworking, and more.
Click here to view the full Executive Summary and Table of Contents now: https://www.bioinformant.com/product/stem-cell-research-products-opportunities-tools-and-technologies/
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the only research firm to serve the stem cell sector since it emerged. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.
Click here to view our global strategic reports for the stem cell industry.